stockrowMedX Health Corp.
MDXHF Healthcare Diagnostics & Research
MedX Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $338,700.00, down 5.23% from fiscal 2024.
- Revenue
- +33.6%
- EPS
- −6.06%
- Free cash flow
- +41.6%
- Total debt
- −8.75%
Quarter to June 2026, against a year earlier
Follow MDXHF
Alert me
MedX Health Corp. (MDXHF) EV/Sales
As of 16 October 2026, MedX Health Corp. (MDXHF) trades at a EV/Sales of 29.4×. Over the past ten years it has ranged from −1.1× (June 2022) to 49.4× (September 2025); the current reading is higher than 93% of that period. That is above the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 12.3× | 107.15% |
| FY2024 | 5.9× | 2,151.02% |
| FY2023 | 0.3× | (58.32%) |
| FY2022 | 0.6× | — |
| FY2021 | −0.9× | — |
| FY2020 | 0.2× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.5× | (65.43%) |
| Mar 2026 | 39.0× | 217.59% |
| Dec 2025 | 12.3× | (74.40%) |
| Sep 2025 | 48.0× | 577.96% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QUCY Quantum Cyber N.V compare | 0.8× |
| MYGN Myriad Genetics, Inc. compare | 0.8× |
| FLGT Fulgent Genetics, Inc. compare | 0.8× |
| PRPO Precipio, Inc. compare | 1.2× |
| BDSX Biodesix, Inc. compare | 2.2× |
| XGN Exagen Inc. compare | 2.6× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 18.6× |
| MDXHF MedX Health Corp. | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. compare | 43.0× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)